SCHEMBL7146192

SCHEMBL7146192

CCOC(=O)c1csc(NC(=O)NCc2ccccn2)n1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.60
SMN1; SMN2 Q16637 5/20 0.60
NPC1 O15118 4/20 0.60
ROCK2 O75116 1/20 0.60
ROCK1 Q13464 1/20 0.60
CYP1A2 P05177 1/20 0.57
CYP2C19 P33261 1/20 0.57
L3MBTL1 Q9Y468 2/20 0.56
TDP1 Q9NUW8 1/20 0.55
LMNA P02545 1/20 0.55
GAA P10253 1/20 0.55
HSP90AA1 P07900 2/20 0.54
MAPT P10636 1/20 0.54
MAPK1 P28482 1/20 0.54
ALDH1A1 P00352 3/20 0.53
KDM4E B2RXH2 3/20 0.53
KMT2A Q03164 1/20 0.52
ALOX15 P16050 1/20 0.52
HSD17B10 Q99714 1/20 0.52
EGFR P00533 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7301734 0.85 SMN1; SMN2 (0.67) RAB9ASMN1; SMN2NPC1ROCK2ROCK1
SCHEMBL7145427 0.84 ROCK2 (0.67) RAB9ASMN1; SMN2NPC1ROCK2ROCK1
SCHEMBL7136723 0.82 ROCK2 (0.50) RAB9ASMN1; SMN2NPC1ROCK2ROCK1
SCHEMBL525057 0.78 RAB9A (0.60) RAB9ASMN1; SMN2NPC1CYP1A2CYP2C19
SCHEMBL20379389 0.77 ALDH1A1 (0.81) RAB9ASMN1; SMN2NPC1L3MBTL1GAA
SCHEMBL354643 0.77 L3MBTL1 (0.59) RAB9ASMN1; SMN2NPC1CYP1A2CYP2C19
SCHEMBL3594194 0.76 RAB9A (1.00) RAB9ASMN1; SMN2NPC1CYP1A2CYP2C19
SCHEMBL2557756 0.75 ROCK1 (1.00) ROCK2ROCK1
SCHEMBL10466253 0.75 ROCK2 (0.55) RAB9ASMN1; SMN2NPC1ROCK2ROCK1
SCHEMBL7139983 0.75 SMN1; SMN2 (0.72) RAB9ASMN1; SMN2NPC1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0928790-B1 Thiazole derivatives HOFFMANN LA ROCHE (CH) 2003-03-05 EP disclosed
US-6344562-B1 ANTITUMOR AGENTS HOFFMANN-LA ROCHE INC. 2002-02-05 US disclosed
US-20020010316-A1 Thiazole derivatives ALIG LEO (CH) 2002-01-24 US disclosed
US-6320054-B1 INHIBIT BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES F CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS. HOFFMAN-LA ROCHE INC. 2001-11-20 US disclosed
US-6100282-A Thiazole derivatives HOFFMAN-LA ROCHE INC. (US) 2000-08-08 US disclosed
EP-0928790-A1 Thiazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 1999-07-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010316-A1 Thiazole derivatives VCAM1, SOST, TGFB1 RAB9A 1440/4885SMN1; SMN2 3186/4885NPC1 987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.